<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cellbxhealth Plc — News on 6ix</title>
    <link>https://6ix.com/company/cellbxhealth-plc</link>
    <description>Latest news and press releases for Cellbxhealth Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cellbxhealth-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57b9ebeedb30cb6f88c2a.webp</url>
      <title>Cellbxhealth Plc</title>
      <link>https://6ix.com/company/cellbxhealth-plc</link>
    </image>
    <item>
      <title>Research Collaboration with The Royal Marsden</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/research-collaboration-with-the-royal-marsden</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/research-collaboration-with-the-royal-marsden</guid>
      <pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
      <description>CelLBxHealth plc has announced a research collaboration with The Royal Marsden NHS Foundation Trust to conduct a clinical study involving 200 patients with advanced non-small cell lung cancer. This study will focus on analyzing circulating tumor cell DNA (CTC-DNA) in patients whose circulating tumor DNA (ctDNA) testing is uninformative, aiming to identify actionable mutations that can guide treatment decisions for this cohort. Results are anticipated by year-end, with the potential to expand tre</description>
    </item>
    <item>
      <title>Board changes - Replacement</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/board-changes-replacement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/board-changes-replacement-1</guid>
      <pubDate>Thu, 16 Apr 2026 16:39:00 GMT</pubDate>
      <description>CelLBxHealth PLC has amended a previous announcement regarding board changes, adding that Non-Executive Director Klaas de Boer holds 2,002,319 ordinary shares, representing approximately 0.18% of the company&apos;s issued share capital. This amendment follows the appointments of Peter Collins as Chief Executive Officer and Klaas de Boer, Kim Oreskovic, and Benjamin Hart as Non-Executive Directors, while Joseph Eid steps down from the board. The company, a leader in circulating tumour cell intelligenc</description>
    </item>
    <item>
      <title>Aligning Regulatory Approach with Commercial Needs</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/aligning-regulatory-approach-with-commercial-needs</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/aligning-regulatory-approach-with-commercial-needs</guid>
      <pubDate>Fri, 13 Feb 2026 07:00:00 GMT</pubDate>
      <description>CelLBxHealth plc is discontinuing the maintenance of its FDA establishment license and device listing for the Parsortix system to align with current commercial needs and strengthen cost discipline, as over 97% of platforms are used for research where the listing offers no commercial benefit. This strategic adjustment allows the company to reallocate resources towards revenue growth, customer support, and product development, while retaining the flexibility to reinstate the listing if advantageou</description>
    </item>
    <item>
      <title>CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-preliminary-fourth-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-preliminary-fourth-quarter-2025-financial-results</guid>
      <pubDate>Fri, 16 Jan 2026 07:26:00 GMT</pubDate>
      <description>GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update ...</description>
    </item>
    <item>
      <title>CelLBxHealth PLC Announces Board Changes</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-board-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-board-changes</guid>
      <pubDate>Mon, 12 Jan 2026 07:10:00 GMT</pubDate>
      <description>GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce ...</description>
    </item>
    <item>
      <title>Cellbxhealth PLC Announces Holding(s) in Company</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-holdings-in-company</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-holdings-in-company</guid>
      <pubDate>Tue, 23 Dec 2025 10:00:00 GMT</pubDate>
      <description>GUILDFORD, SURREY / ACCESS Newswire / December 23, 2025 /Cellbxhealth PLC: TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0034330679 Issuer Name CelLBxHealth plc UK or Non-UK Issuer UK 2. Reason for Notification An ...</description>
    </item>
    <item>
      <title>PDMR Dealing and ESOT Share Purchase</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/pdmr-dealing-and-esot-share-purchase</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/pdmr-dealing-and-esot-share-purchase</guid>
      <pubDate>Fri, 19 Dec 2025 17:51:00 GMT</pubDate>
      <description>Cellbxhealth plc announced that Executive Chairman Jan Groen and Chief Executive Officer Peter Collins each purchased 5,000,000 ordinary shares at 1.0 pence per share, and Finance Director Sinead Armstrong acquired 2,500,000 ordinary shares at the same price, following an oversubscribed placing. Additionally, the trustee of the ANGLE Employee Share Ownership Trust purchased 2,886,742 ordinary shares at 1.1p each, which will be held for employee benefit. Following these transactions, Dr. Groen an</description>
    </item>
    <item>
      <title>Results of General Meeting and Board Changes</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/results-of-general-meeting-and-board-changes-1</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/results-of-general-meeting-and-board-changes-1</guid>
      <pubDate>Mon, 15 Dec 2025 14:41:00 GMT</pubDate>
      <description>Cellbxhealth plc announced that all resolutions were passed at its General Meeting, paving the way for the admission of 816,760,990 New Ordinary Shares to AIM, with the first admission expected on December 16, 2025, and the second on December 18, 2025, bringing the total voting rights to 1,139,402,658. The company also confirmed the permanent appointment of Peter Collins as Chief Executive Officer, transitioning from his interim role, and anticipates four board appointments in January 2026, subj</description>
    </item>
    <item>
      <title>Additional Subscription</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/additional-subscription-2</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/additional-subscription-2</guid>
      <pubDate>Tue, 02 Dec 2025 11:11:00 GMT</pubDate>
      <description>Cellbxhealth plc announced an additional subscription by Conifer Management, LLC, on behalf of the Acacia funds, for 40,891,541 New Ordinary Shares at the Issue Price, raising approximately £0.4 million. This brings the total gross proceeds from the fundraising, including this additional subscription, to approximately £8.2 million. Following this, Acacia will hold 29.9% of the issued share capital. The enlarged share capital post-Second Admission is expected to be 1,139,402,658 New Ordinary Shar</description>
    </item>
    <item>
      <title>Result of Retail Offer</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/result-of-retail-offer-46</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/result-of-retail-offer-46</guid>
      <pubDate>Mon, 01 Dec 2025 17:44:00 GMT</pubDate>
      <description>Cellbxhealth plc has announced the successful closure of its Retail Offer, raising approximately £0.96 million through the issuance of 95,869,449 Retail Offer Shares at 1.0 pence each, subject to the passing of resolutions at a General Meeting on December 15, 2025. In aggregate, the company has conditionally raised £7.8 million at the Issue Price, with a total of 775,869,449 New Ordinary Shares to be issued, resulting in an enlarged share capital of 1,098,511,117 New Ordinary Shares upon admissi</description>
    </item>
    <item>
      <title>Update to Admission of Fundraising Shares</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/update-to-admission-of-fundraising-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/update-to-admission-of-fundraising-shares</guid>
      <pubDate>Tue, 25 Nov 2025 17:40:00 GMT</pubDate>
      <description>Cellbxhealth plc has provided an update on the admission of its fundraising shares, with First Admission of 9,090,000 First Tranche Fundraising Shares expected around December 16, 2025, and Second Admission for up to 770,910,000 Second Tranche Placing Shares, Subscription Shares, and Retail Offer Shares anticipated on December 18, 2025, subject to resolutions being passed.
                Disclaimer*</description>
    </item>
    <item>
      <title>Proposed Placing and Subscription</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/proposed-placing-and-subscription-17</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/proposed-placing-and-subscription-17</guid>
      <pubDate>Mon, 24 Nov 2025 18:32:00 GMT</pubDate>
      <description>Cellbxhealth plc is proposing to raise £6.8 million through a placing, subscription, and retail offer at an issue price of 1.0 pence per share, representing a discount to the previous closing price. The company also plans a share capital reorganisation involving a sub-division of existing ordinary shares. The proceeds will be allocated to research and development (£1.9 million), sales and marketing (£1.0 million), restructuring (£1.1 million), IT systems (£0.2 million), and operating costs (£1.8</description>
    </item>
    <item>
      <title>QIAGEN Collaboration and Co-Marketing Agreement</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/qiagen-collaboration-and-co-marketing-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/qiagen-collaboration-and-co-marketing-agreement</guid>
      <pubDate>Tue, 18 Nov 2025 07:00:00 GMT</pubDate>
      <description>Cellbxhealth plc has announced a non-exclusive Collaboration and Co-Marketing Agreement with QIAGEN Manchester Ltd. to advance circulating tumour cell (CTC) research with pharmaceutical partners. This agreement allows QIAGEN to offer Cellbxhealth&apos;s Parsortix platform alongside its molecular technologies for drug development, biomarker discovery, and companion diagnostic feasibility studies. QIAGEN may contract directly with pharmaceutical partners, outsourcing exploratory CTC projects to Cellbxh</description>
    </item>
    <item>
      <title>CelLBxHealth PLC Presents Proof-of-Concept Study</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-presents-proof-of-concept-study</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-presents-proof-of-concept-study</guid>
      <pubDate>Wed, 05 Nov 2025 07:00:00 GMT</pubDate>
      <description>CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics&apos; workflow at world-leading drug development conference Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study ...</description>
    </item>
    <item>
      <title>Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-expert-consensus-on-ctcs-update-on-funding</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/cellbxhealth-plc-announces-expert-consensus-on-ctcs-update-on-funding</guid>
      <pubDate>Tue, 04 Nov 2025 07:00:00 GMT</pubDate>
      <description>Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years CTCs provide ...</description>
    </item>
    <item>
      <title>CHANGE OF NAME</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/change-of-name-112</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/change-of-name-112</guid>
      <pubDate>Wed, 29 Oct 2025 07:00:00 GMT</pubDate>
      <description>ANGLE plc announced that its application to change its name to CelLBxHealth plc has been registered. Effective October 29, 2025, at 8:00 a.m., the company&apos;s TIDM will change to CLBX on the London Stock Exchange, while its ISIN and SEDOL will remain unchanged. The company&apos;s website address will also change to CelLBxHealth.com, with AIM Rule 26 information accessible on the &quot;Investors&quot; section of the angleplc.com website from the same time. Shareholders&apos; rights remain unaffected, and existing shar</description>
    </item>
    <item>
      <title>Appointments: Interim CEO and senior board advisor</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/appointments-interim-ceo-and-senior-board-advisor</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/appointments-interim-ceo-and-senior-board-advisor</guid>
      <pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
      <description>ANGLE plc, soon to be renamed CelLBxHealth plc, announced the appointment of Peter Collins as interim Chief Executive Officer and Klaas de Boer as a senior advisor to the Board on October 16, 2025. Collins, bringing over 25 years of experience in oncology drug and diagnostics development, previously held senior executive positions, including Chief Executive Officer at SAGA Diagnostics and Chief Business Officer at Inivata. De Boer, with over 25 years of experience in finance and technology, bega</description>
    </item>
    <item>
      <title>Strategy Update</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/strategy-update-19</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/strategy-update-19</guid>
      <pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
      <description>ANGLE PLC announced a revised strategy and a proposed name change to CelLBxHealth plc, reflecting a sharpened focus on CTC intelligence. Dr. Jan Groen, the current Non-Executive Chairman, will become the Executive Chairman to lead this new direction. The company&apos;s strategy emphasizes cost control and accelerated commercial progress. ANGLE plc has a cash runway through to Q1 2026 and anticipates the need to raise funds in the coming months. The company&apos;s AIM ticker will change to CLBX.

         </description>
    </item>
    <item>
      <title>Presentation of Data on Glioblastoma</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/presentation-of-data-on-glioblastoma</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/presentation-of-data-on-glioblastoma</guid>
      <pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
      <description>Presentation of Data on Glioblastoma.</description>
    </item>
    <item>
      <title>Board Changes</title>
      <link>https://6ix.com/company/cellbxhealth-plc/news/board-changes-425</link>
      <guid isPermaLink="true">https://6ix.com/company/cellbxhealth-plc/news/board-changes-425</guid>
      <pubDate>Fri, 12 Sep 2025 06:00:00 GMT</pubDate>
      <description>ANGLE plc announced that Chief Executive Andrew Newland and Finance Director Ian Griffiths have agreed to step down from their positions on the Board following discussions with a significant shareholder. Both Newland and Griffiths intend to support the company with an orderly handover. The Board now consists of Dr. Jan Groen, Non-executive Chairman, and Dr. Joseph Eid, Non-executive Director, with plans to expand the Board in due course.

                Disclaimer*</description>
    </item>
  </channel>
</rss>